Immunotherapy in hematologic malignancies: past, present, and future

CAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens

Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...

Immunotherapy of hematologic malignancies: the road to the future.

Immunotherapy in Urologic Malignancies: The Evolution and Future of Pattern Recognition Receptors

Cellular immunotherapy as a beacon of hope for hematological malignancies

Recently, successful cancer immunotherapy has aroused great interest in application of this approach in hematological malignancies. Immune responsiveness is a key clinical feature of hematological malignancies. Indeed, the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) largely derives from graft-versus-tumor effects that highlight the ability of the immune system to speci...

Sarcoma Immunotherapy: Past Approaches and Future Directions

Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25-50% of patients treated with initial curative intent will develop metastatic disease. In the metastatic setting, chemotherapy rarely leads to complete and durable responses; therefore, there is a dire need for more effective therapies. Exploring immunotherapeutic...